Oct 31, 2018

Is edaravone harmful? (A placebo is not a control)

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
John Turnbull

Abstract

Edaravone is delivered by long-term daily intravenous infusions, yet the risk of infusion was not considered in the design or analysis of studies examining the efficacy of edaravone in ALS. A reappraisal of the pivotal edaravone study (Study 19) on which claims of efficacy are based suggests that this risk cannot be dismissed, that the efficacy of edaravone may be over-estimated, and that some differences between edaravone and placebo may not implicate the ALS disease process. When trial conditions may be harmful to both arms of a placebo-controlled trial, not only is it necessary that treatment prove superior to placebo, but also that treatment is better than no intervention. In Study 19, edaravone performed better than placebo, but both placebo and edaravone likely did worse than no intervention, an interpretation more in keeping with previous trial experience of drugs with similar mechanisms of action, and with previous trial experience with edaravone. Edaravone, as presently delivered, may be both ineffective and harmful.

  • References22
  • Citations3

Citations

Mentioned in this Paper

Study
Phenylmethylpyrazolone
Amyotrophic Lateral Sclerosis
Experience
Pharmacologic Substance
Amyotrophic Lateral Sclerosis 2, Juvenile (Disorder)
Clinical Trials
Analysis
Both Upper Arms
Placebo Control

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Related Papers

Experimental Neurology
Ryosuke Takahashi
Lancet Neurology
Orla Hardiman, Leonard H van den Berg
Nihon rinsho. Japanese journal of clinical medicine
Koji Abe
Lancet Neurology
Makoto AkimotoWriting Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group
© 2020 Meta ULC. All rights reserved